EXPLORE!

FDA Approves Emrelis for c-Met Overexpressing NSCLC

  426 Views

Emedinexus    20 May 2025

The FDA has approved Emrelis, a lyophilized powder for injection, for the treatment of non-squamous non-small cell lung cancer (NSCLC) in patients with high c-Met protein overexpression. Emrelis is a first-in-class antibody-drug conjugate targeting the c-Met protein, offering a new therapeutic option for this aggressive cancer subtype.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.